新股定价 | 银诺医药每股定价18.68港元，公开发售超购逾5340倍、一手中签率0.5%_老虎社区_美港股上老虎

新股定价 | 银诺医药每股定价18.68港元，公开发售超购逾5340倍、一手中签率0.5%

老虎资讯综合2025-08-15

银诺医药-B (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。

银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1142397652?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","is_english":false,"pubTime":"2025-08-15 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142397652","market":"hk","top_or_hot":-1,"title":"新股定价 | 银诺医药每股定价18.68港元，公开发售超购逾5340倍、一手中签率0.5%","media":"老虎资讯综合","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02591\">银诺医药-B</a> (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。</p><p>银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0d50e1beb25b1e9a5585ea369623bdbc\" title=\"\" tg-width=\"502\" tg-height=\"522\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/1e81121aa42d96eba2f5b396824b6065\" title=\"\" tg-width=\"499\" tg-height=\"637\"/></p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股定价 | 银诺医药每股定价18.68港元，公开发售超购逾5340倍、一手中签率0.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股定价 | 银诺医药每股定价18.68港元，公开发售超购逾5340倍、一手中签率0.5%\n</h2>\n\n<h4 class=\"meta\">\n\n2025-08-15 07:57 北京时间&nbsp;&nbsp;&nbsp;<strong>老虎资讯综合</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>银诺医药-B (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药－Ｂ","start_time":0,"source_url":"","article_id":"1142397652","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142397652","pubTimestamp":1755215838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":" $银诺医药-B(02591)$ (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元元。股份预期今日(15日)挂牌。银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02591":"银诺医药－Ｂ"},"translate_title":"New share pricing | Yinnuo Pharmaceutical is priced at HK $18.68 per share, the public offering is oversubscribed by more than 5340 times, and the winning rate of one lot is 0.5%","themeId":"2b827bbc3b346a324213f3d186e2feaf","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/8f38163efae6312f7b6a550f9ab08d54","symbols_score_info":{"02591":1.1},"content_text":"银诺医药-B (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}